Ecovyst reported a 42% sales increase to $250 million in Q2 2026, driven by higher volumes and prices of sulfuric acid products. Net income more than doubled to $10.7 million, with adjusted EBITDA up 27% to $53.1 million. The company completed the acquisition of Calabrian sulfur dioxide business, expanding its market and raising full-year adjusted EBITDA guidance to $195-$207 million. Ecovyst expects continued strong demand in its core markets and synergies from the acquisition to enhance shareholder value.
Avalanche (AVAX) has surged past the $10 mark after breaking out from a consolidation range between $7.00 and $8.20, supported by a sharp increase in trading volume. The price climbed to around $10.27, clearing multiple resistance levels and reclaimi...
Zcash (ZEC) price retreated from a recent high near $1,600 to around $1,443 amid increased selling pressure, signaling a healthy correction after a strong rally. Despite the pullback, technical indicators remain bullish, with ZEC holding above major ...
Avalanche's AVAX price rose 18% due to three key events: New York Life Investment Management launched its first tokenized high-yield bond fund on Avalanche, Paxos added AVAX to its regulated payment services, and a network upgrade on September 22 wil...
Orthocell Ltd has made its first commercial sales of Remplir, a nerve repair product, in Thailand following Thai FDA approval and the appointment of MediTime as its exclusive distributor. This launch opens access to Thailand's estimated $84 million n...
Strategy (MSTR) stock surged 16.39%, closing at $153.92 after heavy trading volume more than doubling its average daily shares. The rise is closely tied to Bitcoin's price, as Strategy holds around 845,000 BTC worth about $69 billion, making Bitcoin'...
